dc.contributor.author |
Mix, M |
en |
dc.contributor.author |
Ramnath, N |
en |
dc.contributor.author |
Gomez, J |
en |
dc.contributor.author |
de Groot, C |
en |
dc.contributor.author |
Rajan, S |
en |
dc.contributor.author |
Dibaj, S |
en |
dc.contributor.author |
Tan, W |
en |
dc.contributor.author |
Rustum, Y |
en |
dc.contributor.author |
Jameson, Michael |
en |
dc.contributor.author |
Singh, AK |
en |
dc.date.accessioned |
2017-09-07T02:31:47Z |
en |
dc.date.issued |
2015-10 |
en |
dc.identifier.citation |
World Journal of Clinical Oncology 6(5):156-165 Oct 2015 |
en |
dc.identifier.issn |
2218-4333 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/35546 |
en |
dc.description.abstract |
AIM: To prospectively determine the safety and tolerability of oral L-selenomethionine (SLM) with concurrent chemoradiation (CCRT) for Stage III non-small cell lung cancer (NSCLC) and estimate if the incidence and/or severity of adverse events could be reduced by its use. METHODS: Sixteen patients with stage III NSCLC were accrued to this single arm, phase II study. CCRT consisted of radiation given at 2 Gy per fraction for 30-33 fractions, 5 d per week with concurrent weekly IV paclitaxel 50 mg/m(2) followed by carboplatin dosed at an area under the time-concentration curve of 2. SLM was dosed in a loading phase at 4800 mug twice daily for one week prior to CCRT followed by once daily dosing during treatment. RESULTS: No selenium-related toxicity was observed. Analysis revealed grade 3 or higher esophagitis in 3 of 16 patients (19%), pneumonitis in 0, leukopenia in 2 (12.5%), and anemia in 1 (6%); the latter two were significantly reduced when compared to the protocol-stated expected rate of 35% (P = 0.045 for leukopenia, and P < 0.01 for anemia). Median overall survival was 14.9 mo and median failure-free survival was 9 mo (95%CI: 3.3-21.5). CONCLUSION: There may be some protective benefit of selenium in the setting of CCRT for inoperable NSCLC. The data suggests decreased rates of myelosuppression when compared to similarly-treated historical and contemporary controls. Further evaluation of selenium in this setting may be warranted |
en |
dc.publisher |
Baishideng Publishing Group Co. Limited |
en |
dc.relation.ispartofseries |
World Journal of Clinical Oncology |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/2218-4333/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
https://creativecommons.org/licenses/by-nc/4.0/ |
en |
dc.title |
Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.5306/wjco.v6.i5.156 |
en |
pubs.issue |
5 |
en |
pubs.begin-page |
156 |
en |
pubs.volume |
6 |
en |
dc.description.version |
VoR - Version of Record |
en |
dc.rights.holder |
Copyright: The authors |
en |
pubs.end-page |
165 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
602893 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Waikato Clinical school |
en |
dc.identifier.eissn |
2218-4333 |
en |
pubs.record-created-at-source-date |
2016-12-19 |
en |